Abstract
Objectives: Surgical cytoreduction is a critical component of primary therapy for advanced ovarian cancer. However, patients who die within 90 days of cytoreductive surgery do not benefit from the operation and may experience significant harm. We investigate the association between age and 90-day postoperative mortality after cytoreductive surgery, and how neoadjuvant chemotherapy (NACT) modulates this association.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
